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ABSTRACT 
An abstract of the thesis of Collin M. Shaw for the Master of 
Science in Biology presented November 9,1998. 
Title: Increased glutathione metabolic defense capabilities In 
cultured Alzheimer's diseased lymphoblast cell lines. 
The hypothesis to be tested states that the pathology of 
Alzheimer's disease (AD) involves elevated levels of oxidative 
stress, resulting in elevated levels of cellular oxidative defense 
mechanisms. If the premise is true, than AD pathologically 
afflicted cells should have a higher demand for glutathione (GSH) 
as an innate oxidative defense mechanism hence; greater GSH 
concentrations, increased GSH resynthesis capabilities, and 
increased levels of cystathionine gamma-lyase (CNase). 
Alzheimer diseased and age matched control lymphoblast cells, 
obtained from OHSU's Oregon Brain Aging Study, were cultured, 
and GSH biochemistry was subsequently evaluated. GSH was 
depleted by exposing cells to the GSH depleting agent 
diethylmaleate (DEM) and the resulting GSH concentrations were 
measured. GSH resynthesis was measured after depleting GSH 
with DEM, to a level of approximately half base GSH concentration, 
then removing the depleting agent, resuspending the cells in fresh 
medium (DEM-free), and subsequently measuring GSH levels. 
GSH concentrations were measured by HPLC, and all data was 
normalized to cellular protein concentration. Cellular CNase 
specific activity levels were measured by adding cytasthionine, the 
CNase substrate, and then measuring the amount of cysteine 
produced by means of the DTNB assay. The AD cell lines showed 
no increase in base levels of GSH as compared to control cell lines. 
The AD cell lines showed a statistically significant increase in GSH 
resynthesis capabilities and cystathionine gamma-lyase specific 
activity levels. These findings add further weight to the AD 
oxidative stress hypothesis, which is based on the premise that the 
causative agent of AD pathogenesis is an increase in the level of 
cellular free radicals produced. 
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ABBREVIATIONS USED 
(AD) Alzheimer's disease 
(Apo E) Apolipoprotein Epsilon 
(APP) Amyloid beta precursor protein 
(~-AP) Beta-Amyloid protein 
(BCA) Bicinchoninic acid 
(BSA). Bovine Serum Albumin 
(CAT) Catalase 
(cm) Centimeter 
(cDNA) Complimentary DNA 
(CNase) Cystathionine gamma-lyase 
(COX) Cytochrome c Oxidase 
(C02) Carbon Dioxide 
(cys-) Cysteine Thiolate ion 
(DEM) Diethyl maleate 
(ETC) Electron transport chain 
(e4) Apolipoprotein E epsilon 4 
(FDNB) Fluoro-2, 4-dinitrobenzene 
(g) Gravity 
(g-GG) Gamma-glutamyl glutamate 
(GPX) GSH peroxidase 
(GS-) Glutathione Thiolate Ion 
(GSH) Glutathione 
(GSK3b) Glycogen synthase kinase 3 Beta 
(GSSG) Oxidized form of GSH 
(GSSG-R) GSH reductase 
(GST's) Glutathione transferases 
(HNE) E-4-hydroxy-2-nonenal 
(HPLC) High Pressure Liquid Chromatography 
(KCI) Potassium Chloride 
(KOH) Potassium Hydroxide 
(KHC03) Potassium Bicarbonate 
(MDA) Malondialdehyde 
(J.lI) Microliter 
(~lmols) Micromoles 
(mM) Millimolar 
(J.lM) Micromolar 
(J.lg) Microgram 
(mg) Milligram 
(mtDNA) Mitochondrial DNA 
(NaOH) Sodium Hydroxide 
(N) Normality 
(nDNA) Nuclear DNA 
(nM) Nanomoles 
(NFT) Neurofibrillary tangle 
(OBAS) Oregon Brain Aging Study 
(OH8dG) 8-hydroxy-2'-deoxyguanosine 
(OHSU) Oregon Health Sciences University 
(peA) Percloric acid 
(PHF) Paired helical filament 
(PHF -t) Hyperphosphorylated tau protein 
(PLP) Pyridoxal 5'-phosphate 
(RNS) Reactive Nitrogen Species 
(ROM) Reactive Oxygen Metabolites 
(ROS) Reactive Oxygen Species 
(RPMI) Roswell Park Memorial Institute 
(SOD) Superoxide Dismutase 
(SDS) Sodium Dodecyl sulfate 
(SP's) Senile plaques 
(TBARS) Thiobarbituric acid-reactive products 
(TNF) Tumor Necrosis Factor 
(TPKI) Tau protein Kinase I 
(TPKII) Tau protein Kinase II 
INTRODUCTION 
Clinically, Alzheimer's disease (AD) is characterized by 
gradual progressive intellectual deterioration. Clinical symptoms 
begin with a subtle, and poorly recognized, degeneration of 
memory. Slowly memory loss becomes more noticeable and will 
eventually become incapacitating, resulting in dementia. Other 
common symptoms include confusion, poor judgement, linguistic 
difficulties, agitation, withdrawal, and hallucinations. Some 
patients may even develop Parkinsonian symptoms, seizures, 
urinary and fecal incontinence, and fluent aphasia. Terminally ill 
patients are mute, and may develop flexion contractures. 
Pulmonary and urinary tract infections reSUlting in systemic 
sepsis, commonly cause death to afflicted AD patients (Morrison­
Bogorad, 1993). Pathologically, AD is characterized by the 
neuronal presence of neurofibrillary tangles (NIT's), senile 
plaques (SP's), Hirano bodies, granulovacuo1ar degeneration, 
synaptic loss and selective neuronal loss. 
In 1907 A10is Alzheimer, a German neuropathologist and 
psychiatrist, initially noted AD. Dr. Alzheimer described the 
hallmark pathological findings in a 51 year-old woman, who 
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presented a continuing memory loss, ultimately to the state of 
dementia. Upon autopsy of the afflicted patient, Dr. Alzheimer 
described the presence of NIT's, a loss of cerebral cortical 
neuronal mass, and the presence of numerous SP's (Markesbery, 
1997). The contemporary pathologists, of 1907, suggested that 
severe arteriosclerosis was at the heart of these pathological 
findings. It was not until the 1960's, when researchers and 
clinicians had a better understanding of neurotransmitters and 
access to specific cortical maps, that a specific neurological 
disease (a separate entity from arteriosclerosis) dubbed 
Alzheimer's Disease was recognized. Since the 1980's, advances 
in molecular biological approaches have led to the more 
pathologically descriptive understanding of the cellular and 
molecular processes involved in AD pathogenesis. 
(NEUROFIBRILLARY TANGLES) 
Neurofibrillary tangles in Alzheimer's diseased brains are 
commonly found in the hippocampus, neocortex, and many 
subcortical nuclei. The hippocampus is involved in the 
development of short-term memory and the integration of that 
information into long term memory. The neocortex is associated 
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with higher cognition, and the size of the neocortex is proportional 
to increasing evolutionary cognition (Shephard, 1994a). 
The NFT's consist of abnormally paired helical filaments 
(PHF's), which are composed of hyperphosphorylated tau (PHF-t) 
proteins and are laden with small amounts of ubiquitin (Mori, 
1987). The tau protein is one of the many microtubule-associated 
proteins and is utilized in promoting the stability of axonal 
microtubules. Axonal microtubules function essentially, as 
railroad tracks for intra-neuronal and intra-axonal transport 
(Shephard, 1994b). Tau proteins become hyperphosphorylated 
throughout the AD pathological process. The enzymes that 
phosphorylate the tau proteins are thought to be tau protein 
kinase I (TPK I) and tau protein kinase II (TPK II) (Imahori, 1997). 
Sequence analysis of TPK I complimentary-DNA (cDNA) has 
provided convincing evidence that the enzyme is actually glycogen 
synthase kinase-3-beta (GSK3b) (Ishiguro, 1993). 
The enzymatic sequence of tau phosphorylation by TPK I 
and II is convoluted. TPK I can only phosphorylate non-native tau 
proteins that have been abnormally phosphorylated, but cannot 
phosphorylate tau proteins that have not been abnormally 
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phosphorylated. TPK II can phosphorylate both native and non­
native tau proteins, regardless of whether the protein has 
previously been phosphorylated (Imahori, 1997J. It is theorized 
that TPK I and TPK II act in concert to regulate one another. 
Once TPK I is activated, the active enzyme converts native tau 
proteins into PHF-tau proteins (Imahori, 1997J. What activates 
TPK I and TPK II? Imahori, et al. theorized that amyloid beta 
protein (~-AP) occurs in neuronal cells before the phosphorylation 
of native tau protein is induced (Imahori, 1997J. They tested this 
hypothesis by adding 20 flM ~-AP to primary tissue cultures of 
embryonic rat hippocampal cells. After three hours the cells were 
stained with anti-TPK I antibody. The results showed that after 
the introduction of ~-AP the statistical quantit.y and the activity of 
TPK I increased. These results suggest that upon the 
introduction of ~-AP, the activity of TPK I is induced, leading to 
the phosphorylation of PHF into PHF-tau proteins. The 
researchers also analyzed the survival of ~-AP cultured cells 
versus control cells and found only 10% of the ~-AP cultured cells 
survived as compared to control cells. When the same experiment 
was repeated, this time with the addition of actinomycin-D and/or 
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cyclobexamide to the medium containing the ~-AP, hippocampal 
cell death was prevented. Application of the anti-transcriptional 
and anti-translation8l agents suggests that ~-AP induction ofTPK 
I activity induced programmed cell death (apoptosis) to occur 
within the hippocampal cell culture. The investigators concluded 
that hyperphosphorylation was ultimately induced by ~-AP, 
which then stimulated oxidative induction (from an unknown 
molecular species) of TPK II and ultimately TPK I. This would lead 
to a disruption of axonal transportation, and eventually to cell 
death by apoptosis. 
(BETA-AMYLOID PROTEIN) 
Since 1968, there have been direct correlations observed 
between the density of SP's found within the brain of post-mortem 
Alzheimer's diseased patients and the severity of clinical dementia 
presented by those patients prior to death (Perry, 1978). Typical 
SP's, averaging some 50 micrometers in diameter, are found 
congregated within extracellular neuronal spaces and can be 
classified into four types (Iverson, 1995). The four types vary by 
morphological characteristics: diffuse, primitive, neuritic, and a 
compact structure. SP's are spherical extracellular lesions that 
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were originally identified and classified by the use of silver-based 
histological stains. The central deposit of the SP's is composed of 
amyloid fibrils, and is surrounded by dystrophic neurites 
(dendrites and axon terminals), activated microglia, and reactive 
astrocytes (Iverson, 1995). All four categories of SP's are 
distributed predominantly within the cerebral cortex, particularly 
the frontotemporal cortex and the hippocampus. 
. Neuritic SP's contain a 6-10 nanometer ~-AP, which is the 
predominant component of the amyloid fibrils. The ~-AP protein 
contains 40-43 amino acids and is derived from amyloid beta 
precursor protein (APP). The APP is a ubiquitous transmembrane 
glycoprotein. Currently, it is unknown how ~-AP becomes 
involved with senile plaque etiology. One hypothesis is that 
neuritic SP's are formed following neuronal cell death from the 
remnants of neurons containing NIT's (Pike, 1993). This theory 
suggests that the SP's are the result of neuronal damage. Other 
theories suggest that SP deposits are induced by the deposition of 
~-AP. Alzheimer's disease has been linked to a mutation on the 
APP sequence or to a mutation on ~-AP sequence itself (Iverson, 
1995) (as described below in AD genetic risk factors). There are 
6 

two predominant hypotheses relating ~-AP mutations to 
derivations of SP's. First: ~-AP results from a point mutation in 
the APP cleavage mechanics leading to the catabolic 
overproduction of ~-AP. Second: a mutation in the cleavage 
mechanism for producing ~-AP from APP results in a more 
insoluble 42 amino acid ~-AP. 
(GENETIC RISK FACTORS) 
.Sporadic (non-mendalian) AD and all familial cases of AD 
appear to have the same phenotypic pathological and clinical 
hallmarks, although genotypically they differ. Alzheimer's disease 
can be divided into four main categories based on genetics 
(Blacker, 1998 & Dewji, 1996). Alzheimer's disease associated 
with Down's syndrome (trisomy 21), occurs in less than 10/0 of AD 
patients. Early onset AD occurs before the age of 65, represents 
5% of AD patients, and is associated with three different genetic 
mutations. Late onset AD afflicts 10-250/0 of all AD patients and is 
associated with a mutation on chromosome 19, resulting in a 
mutation of apolipoprotein E. Sporadic AD, occurs in about 75% 
of all AD afflicted individuals, and has a variety of etiologies, 
including mitochondrial mutations. 
7 
Down's syndrome is caused by an extra (normal) copy of 
the APP gene, located on chromosome 21 (Hardy, 1997). Nearly 
all persons afflicted with a genetic mutation on chromosome 21, 
resulting in Down's Syndrome, will eventually develop cognitive 
decline and will inevitably show all the neuropathological 
hallmarks of AD by the age of 40 (Brugge, 1994). Both AD and 
Down's syndrome show the common etiological pathology of an 
increase in the ~-AP deposition resulting in cellular death. 
Early onset familial AD can be divided into three categories, 
AD1, AD3, and AD4. Alzheimer's disease 1 afflicts about 10% of 
the early onset AD patients and is associated with a mutation on 
chromosome 21, which regulates Apolipoprotein, producing an 
over abundance of APP. AD3 is caused by mutations in the 
presenilin 1 gene located on chromosome 14 (Schellenberg, 1992). 
The functions of presinilin are not known as of yet, but it is 
thought to be an ion channel, a G-coupled receptor, or thought to 
interact with the metabolism of APP, or ~-AP. The mutations in 
the presinilin genes cause an increased production of insoluble 
B-AP resulting in neuronal damage. AD4 is caused by a point 
mutation on chromosome 1, specifically at the site of the 
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presinilin 2 gene. Again, the mutation on the presinilin 2 gene 
results in an overproduction of ~-AP. 
Late onset familial AD, categorized as AD2, effects 10-25% 
of the AD population and is associated with a mutation on the 
apolipoprotein E (Apo E) gene on chromosome 19 (Martinez, 
1998). There are three different Apo E gene alleles distributed 
throughout the population: Apo E-e2, -e3 and -e4. A person 
inherits one form of the alleles from each parent, resulting in six 
possible genotypes. The Apo E-e4 allele has been theorized to 
have a dose related effect when affiliated with AD pathology. It 
was found that persons with two Apo E-e4 alleles had a nine-fold 
increased risk and an earlier onset distribution of AD than those 
with no Apo E-e4 alleles (Corder, 1993). Persons with one Apo E­
e4 allele had a three-fold increased risk and a younger age of 
onset than patients with no Apo E-e4 alleles. Currently no 
relationship as to how Apo E-e4 effects the pathogenesis of AD is 
understood. Elevated cholesterol and low-density lipoprotein 
levels have been associated with the presence of Apo E-e4 alleles 
(Kamboh, 1998). 
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Sporadic AD represents the majority of AD patients and a 
non-mendalian genetic epidemiology can be presumed. Sporadic 
AD can be related to head trauma, cigarette smoking (or other 
oxidative damaging mechanisms), and environmental factors such 
as viruses and/or bacteria. Many theories also relate a mutated 
mitochondrial genome to sporadic AD pathology 
Mitochondria are involved in the respiration of individual 
cells. , Mitochondria are responsible for the reduction of oxygen to 
water and the production of ATP through the employment of a 
sequence of proteins know collectively as the electron transport 
chain (ETC). Mitochondria carty their own DNA, which codes for 
13 polypeptides integral to the ETC and 24 rRNA molecules 
utilized in the production of those 13 polypeptides. Mitochondria 
are replicated strictly by binary fision, meaning that all the 
mitochondria present within an animal or a plant cell have come 
directly from the mother's oocyte of that animal or plant cell via 
binary fision. 
Sporadic AD exhibits protein defects within ETC complex 4, 
specifically the cytochrome c oxidase (COX), which is encoded by 
the mitochondrial genes COl and C02 (Davis, 1997). COX 
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activity has been reported to be reduced in blood platelets (Parker, 
1990), cultured skin fibroblasts (Petersen, 1986), and the brain 
tissue of AD patients (Kish, 1992). The ETC mutation gives rise to 
an increased number of reactive oxygen metabolites (ROM's) 
within the mitochondria. ROM examples include superoxide 
radicals, hydroxyl radicals, and hydrogen peroxide. Normal 
mitochondrion biochemistry results in the discharge of about 2­
3% high energy electrons, which ultimately will produce ROM's. A 
mutation in the ETC ultimately can lead to an even higher 
discharge of high energy electrons, resulting in the increased 
production ROM's and consequently to an increase in oxidative 
damage. 
For any familial or sporadic genetic risk factor classifying 
AD, a common theme can be implied: the increase of insoluble ~­
AP and/or overall increase in oxidative damage (as described 
above). If AD is a collection of different molecular pathologies 
resulting in one common histological presentation, then a 
common biochemical pathway resulting from many different 
genetic and environmental insults can be inferred. The most 
common form of pathology coexisting with AD is an increase in 
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oxidative damage. The brain is relatively vulnerable to oxidative 
free radical damage because of its high oxygen consumption rate, 
abundant lipid content, and relatively insufficient number of 
antioxidant enzymes (Coyle, 1993). 
An increase in ~-AP elevates oxidative damage (Behl, 1992). 
Yankner and colleagues first showed that ~-AP fragments were 
cytotoxic to cells in 1989. They did this by digesting ~-AP into 
smaller fragments, and applying these digested polypeptides 
directly to both primary hippocampal neurons and to clonal 
neuronal cell lines. After the application of digested protein 
fragments the researchers noted neuronal cell death (Yankner, 
1990). Behl, et al. (1994) tested rat cortical neurons for damage 
caused by direct application of ~-AP. These researchers described 
that within an hour after the addition of ~-AP the neuronal cell's 
membranous organelles (golgi and mitochondria) began to show 
evidence of ultrastructural damage, and/or deterioration. The 
implication was that free radicals were at the root of neuronal 
cellular damage, since ROM's cause membrane damage. It has 
been shown that vitamin E and other lipophilic antioxidants 
protected the neuronal cell lines from ~-AP toxicity (Behl, 1992). 
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The damage inflicted on neuronal cells is caused as ~-AP exerts a 
cytotoxic effect on neurons by binding to microglia's mononuclear 
phagocyte scavenger receptor A. This binding stimulates 
microglia to produce neurotoxins, such as reactive oxygen species 
(ROS), reactive nitrogen species (RNS), tumor necrosis factor 
alpha (TNF-a), and Apo E (Ikeda, 1998). In addition, ~-AP 
stimulates the activation of the complement cascade proteins. All 
of these microglial products ultimately lead to neurotoxicity 
through inflammation and apoptosis (Ikeda, 1998). 
The cellular antioxidant glutathione (GSH) was discovered 
in 1888 and acquired the name philothion, which is Greek for 
'love-sulfur' (Cooper, 1997). In 1930, the structure of GSH was 
determined to be a tripeptide composed of glutamate, cysteine, 
and glycine. The chemical name for GSH is y-Glutamyl­
cysteinylglycine. The y-gluatmyl bond connecting glutamate and 
cysteine are resistant to the enzymatic cleavage by cellular 
peptidases, allowing GSH to be relatively stable in both the 
cellular, and the extra-cellular environments. The majority of 
cellular GSH is present in the cytosolic compartment while about 
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20% of GSH can be found within the mitochondria (Cooper, 1997). 
In the mitochondria, GSH serves as an important defense 
mechanism against ROM's created from the process of electron 
transport oxidative phosphorylation. Compartmentalization of 
GSH pools also occurs in the brain. Cerebral GSH pools are 
segregated in the non-neuronal cells, including the glial cells, 
astrocytes, and/or in axons and nerve terminals. 
.Glutathione, which is present ubiquitously in plant, 
bacterial, and animal cells, plays an essential role in free radical 
detoxification. I t does so by cycling between the reduced thiol 
form (GSH) and an oxidized form (GSSG) in which two GSH 
tripeptides are linked together by a disulfide bond. The 
GSH/GSSG cycling is catalyzed by two enzymes: GSH reductase 
(GSSG-R) and GSH peroxidase (GPX). The cycling between the 
reduced and oxidized forms allows GSH to react with and 
neutralize many harmful molecules enzymatically. Glutathione is 
reactive towards free radicals by donating its sulfhydryl (-SH) 
hydrogen atom to most carbon, oxygen (e.g. hydrogen peroxide 
H20 2), and nitrogen free radicals (ROM's), forming GS- (thiolate 
ion), which can react with another GS- to form GSSG. 
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2GSH + H202 ) GSSG + 2H20 
Glutathione is the substrate for many enzymes; three of 
great significance relative to the buffering effects of GSH are 
Glutathione S-transferases (GST) , GSSG-R and GPX. The 
selenium-containing enzyme, GPX enzymatically scavenges toxic 
peroxides and other free radicals, neutralizing them by reducing 
them with the hydrogen ion from the GSH sulfydryl group, as 
described above. 
GSH + ROM + GPX ) GS- + ROMH + GPX 

GS- + GS- ) GSSG 

The oxidation of GSH produces GSSG, then GSSG-R 
reduces GSSG, with help of the cofactor NADPH, reproducing two 
reduced GSH molecules. 
GSSG + GSSG-R + NADPH + H+ -----+) 2GSH + GSSG-R + 
NADP+ 
The GSH sulfhydryl group conjugates to a variety of 
acceptor molecules that need to be biologically neutralized. The 
sulfhydryl group is involved in nucleophilic reactions; nucleophilic 
addition to a double or triple bond, nucleophilic elimination (of a 
halide), and nucleophilic displacement. Glutathione transferases 
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are a class of enzymes which catalyze the conjugation of GSH to 
electrophilic substances (RX), forming the corresponding GSH S­
conjugates (RSG). These conjugate molecules include many 
xenobiotics (such as organophosphates, allylic compounds, and 
epoxides) all of which become relatively unreactive and soluble 
when combined with GSH. 
GSR + RX + GST ------~) RSG + HX + GST 
.When these compounds become neutralized by GSH 
conjugation, they are no longer highly electrophilic and hence no 
longer toxic to cells. The GSH S-conjugates can thus be efficiently 
cleared out of tissues, because of increased solubility and limited 
reactivity. 
Glutathione synthesis is dependent upon the presence of 
limiting cysteine. Intracellular cysteine levels are usually low, due 
to the primary sulfhydryl toxicity of cysteine at elevated 
concentrations. Cysteine toxicity is a consequence of cysteine 
reactivity with protein mixed disulfides, alpha-keto acids, 
chelation of metals, and many other properties of this highly 
reactive amino acid. Cysteine undergoes disulfide exchange with 
protein mixed disulfides, causing a denaturation of some protein's 
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native states (Reed, 1983). Cysteine combines with alpha-keto 
acids and forms stable crystalline hemithioketals, resulting in 
denatured proteins and polypeptides (Cooper, 1997). 
Cystathionine gamma-lyase (CNase) is capable of providing 
cysteine for cell use by utilizing the sulfur atom of methionine and 
the carbon skeleton and amine group of serine, through the 
transulfuration pathway. Methionine enzymatically looses its 
gamma methyl group, forming homocysteine. Homocysteine then 
condenses serine to form the thioether cystathionine, through the 
catalysis of the enzyme cystathionine synthetase. The pyridoxal 
5'-phosphate (PLP) dependent enzyme, CNase, enzymatically 
cleaves L-cystathionine into alpha-ketobutyrate, ammonia, and L­
cysteine. 
CHase + PLP + L-Cystathionlne ---~) CHase + PLP + 
alpha-ketobutyrate, ammonia, and L-cystelne 
Cystathionine is a thioether containing amino acid with no 
known functions, except to serve as an intermediate in the 
transulfuration pathway. The transulfuration pathway is a major 
source of cysteine when the rate of GSH biosynthesis is high, or 
when cysteine concentrations are limiting (Reed, 1995) 
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The adult brain normally relies almost exclusively on the 
oxidation of glucose to meet its high energy demands. In the 
brain, hydrogen peroxide results from oxidative metabolism in the 
mitochondria, and from a variety of other sources including the 
monoamine oxidases, d-amino acid oxidases, and catacholamine 
autoxidation. 
Other toxic oxygen species produced systemically and in the 
brain include singlet oxygen (1°2), superoxide free radicals (02-), 
and peroxides (022-) (Brock, 1984). Chemical activation from 
cytochromes and flavins induces 102 formation from biologically 
ground state triplet oxygen (02)' Singlet oxygen is also chemically 
formed by peroxysomal enzyme catalysis. Formed in transiently 
small amounts during respiration and from light activation, ° 2- is 
very reactive and can easily cause damage to lipids and other 
biochemical components. Hydrogen peroxide is an example of 
0 22- and peroxides are produced by two electron reduction of 
ground state 02­
Pathologically, the genetic disruptions that occur in AD lead 
to an overload of free radicals; some created by ~-AP activation of 
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microglia and/or the ETC COX mutation, and some created by 
normal biological chemistry. 
To defend against these oxidative insults, cells have 
developed cellular defense systems, which include GSH and the 
enzymes catalase and superoxide dismutase. Catalase is limited 
to the peroxisomal compartments within cells. Superoxide 
dismutase converts the superoxide anion radical into the less 
active but relatively stable species, hydrogen peroxide. Thus the 
brunt of the free radical detoxification process, defending against 
and neutralizing hydrogen peroxide, is dependent on GSH's 
antioxidant capabilities. 
(SYNOPSIS OF EXPERIMENTATION) 
In these experiments GSH concentration and GSH resynthesis 
capabilities in AD afflicted lymphoblasts and non-afflicted age 
matched control lymphoblasts were measured and subsequently 
evaluated. The theory being tested is that if AD cells are 
continuously under increased oxidative stress, then the 
Alzheimer's diseased cell capacity to defend against any oxidative 
insult should be greater than the defense capacity of comparable 
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non-afflicted control cells. Control and AD lymphoblasts were 
used throughout these experiments because their mitochondria 
are the same as the mitochondria of neurological cells (since 
direct binary fision from the mother's oocyte's mitochondrial pool, 
produces all cellular mitochondria). 
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METHODS&MATERIALS 
Roswell Park Memorial Institute medium 1640 (RPMI), 
Glutamine, Streptomycin and Penicillin, were purchased from 
Sigma chemical company, St. Louis, MO. Bovine calf serum was 
purchased from Hyclone laboratories, Logan, UT. Flasks were 
purchased from Falcon plastics, Boston, MA. Lymphoblasts from 
Alzheimer's diseased patients and lymphoblasts from control 
patients were donated from the Oregon Brain Aging Study (OBAS) 
at Oregon Health Sciences University (OHSU). The AD donors 
were post mortem histologically confirmed Alzheimer's diseased 
positive. The age matched control cells were obtained from 
persons of similar age, sex, lifestyle, geographic area, ethnicity, 
and trauma backgrounds by the OBAS. The cell lines that were 
investigated are listed below in Table 1. AD1085, AD864, & 
ADl137 represent Alzheimer's diseased cell lines and Co152, 
Co166, & Co203 represents lymphoblast cell lines from the 
Oregon Brain Aging Study whom were control subjects. 
TABLE 1. Lymphoblast ceU lines investigated 
Cell Line Sex of donor 

AD 1085 

AD 1137 

AD 864 

Co 152 

Co 166 

Co 203 

Female 

Female 

Male 

Female 

Female 

Male 
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Anchorage independent lymphoblast cell lines were grown 
in RPMI 1640 (pH of 7.45) supplemented with 4 mM L-glutamine; 
(100 Jlg/ml) streptomycin; (100 units/ml) penicillin G sodium; 
and 11% bovine calf serum. The cell lines were individually 
maintained in 500 ml and 1000 ml volume Erlenmeyer flasks with 
sponge closures. Cell suspensions in the flasks were always kept 
below a level of one inch, allowing normal oxygen metabolism to 
thrive. Cell suspensions in volume flasks were incubated at 37°C 
and a six percent carbon dioxide water saturated atmosphere. 
Lymphoblast cultures were diluted on a tri-weekly basis to an 
optimal cell density of 1.5 x 106 cells/ml. Cell density was 
counted using a Reichert Bright Line hemocytometer and an 
Olympus optical CK2 lOx inverted Phase-contrast light 
microscope. 
Medium was routinely changed by centrifuging cellular 
suspensions (Beckman TJ-6 centrifuge 5 minutes at 1000 x g), 
removing the medium superior to the cell pellet, and then 
replacing with fresh medium. A volume of fresh medium was 
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added which was necessary to yield an optimal 1.5 x 106 
cells/ml. 
Cells were grown for at least two weeks in the medium 
before beginning any studies. This allowed the cells to adapt to 
the culture conditions. 
To prepare for assays, cell density was counted the day 
before the assay was to be performed. Cells were centrifuged in 
polypropylene centrifuge tubes at 1,000 x g (for 5 minutes) and 
resuspended in fresh medium to an optimum cell density of 3 x 
106 cells/ml for the aSH depletion and resynthesis assays and 5 
x 106 cells/ml for the cystathionase assays. After centrifugation, 
cells were pre-incubated in RPMI 1640, and placed in 25 cm2 
polystyrene tissue culture flasks. The cells and the flasks were 
then positioned on their side, in a 37°C incubator, overnight. 
aSH Depletion Assay 
Cell density was determined the day of the experiment and 
recorded. Flasks containing cells were removed from the 
incubator and gently shaken to evenly distribute all cells. A 
quantity of cell suspension was prepared (13 mls) which would be 
adequate for six one ml samples, allowing for one extra ml. 
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Protocol; GSH depletion preparation: A one ml sample of 
suspension was removed from the flask and added to an 
appropriately labeled 1.5 ml microfuge tube. The microfuge tube 
was centrifuged at 13,000 x g in a Fisons micro centaur 
centrifuge for 20 to 30 seconds. The supernatant liquid was 
removed and discarded with a disposable pipette. Next 500 ,.11 of 
10% perchloric acid (PCA) and 15 J.1,1 of 1 J.1,mole / ml gamma­
glutamyl glutamate (y-GG) was added to the cells left from 
centrifugation. The protocol was repeated twice for each time 
allotment. Tops were closed on the now prepared microfuge tubes 
were placed in a rack, at room temperature, until the remainder 
of the assay was completed. 
To the residual cells, remaining in the tissue culture flask, 
diethyl maleate (DEM) (DEM 1:10 dilution in DMSO) was added to 
a final concentration of 200 mM DEM. The DEM used was 98% 
pure. Addition of the DEM was designated as time zero. The 
tissue culture flasks were then returned to the 37°C incubator. At 
time points of 15, 30, 45, 60, and 90 minutes tissue culture 
flasks were removed from the incubator, and a one ml sample of 
cell suspension was extracted and treated as previously described 
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for the GSH depletion preparation. Duplicate samples were 
removed and treated at each time point. The sample microfuge 
tubes were placed in a tube rack, at room temperature, for the 
duration of the experiment. 
PROTEIN ASSAYAND HPLC PREPERATION 
From the GSH depletion assay, microfuge tubes containing 
AD and control cell lines (immersed in PCA and g-GG) were 
centrifuged at 12,000 x g for 20 minutes, at 3°C (Fisons micro 
centaur centrifuge). After centrifugation, microfuge tubes were 
removed and the supernatant was transferred to the 
corresponding labeled 4 ml yellow disposable culture tube, and 
left uncovered. 
A quantity 250 J11 of 30 mM NaOH in 10/0 sodium 
dodecylsulfate (SDS) was added to the precipitated protein pellets 
in the microfuge tubes. The microfuge tubes were placed in a 
refrigerator at 4°C until the protein assay could be completed. 
Yellow disposable culture tubes were utilized in order to 
minimize ultra-violet light exposure and inhibit degradation of 
susceptible compounds. To each yellow tube containing the cell 
supernatant, 50 J11 of 15 mg iodoacetic acid in 1 ml of 0.2 mM 
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meta-cresol purple was added. Then 500 J.lI (added in increments 
of 100 J.lI) of 2 normal (N) potassium hydroxide (KOH) in 2.4 N 
potassium bicarbonate (KHC03) was added to the yellow tubes. 
Next, the yellow tubes were placed in the dark (at room 
temperature) for more than 2 hours, to allow C02 to escape. After 
at least 2 hours, 500 J.lI of 1% (vIv) fluoro-2,4-dinitrobenzene 
(FDNB) in 950/0 ethanol was added to each tube. The tubes were 
then 'capped and again placed in the dark (at room temperature) 
for at least 6 hours, to allow formation of N-DTNB derivatives for 
measurement of GSH by HPLC. 
The glutathione concentration was determined using a 
method of HPLC (Fariss, 1987). Yellow tube HPLC samples were 
centrifuged at 2000 x g for 10 minutes (Beckman TJ-6 centrifuge). 
The supernatants were analyzed for GSH, using a Spectra Physics 
8700 high-performance liquid chromatograph, equipped with a 
LDC UV-III detector and a Hewlett Packard 8390A recording 
integrator. The internal standard, y-GG (15 J.lmole/ml), was used 
as a reference. All GSH concentrations were derived using 
quantity/ml data relative to the y-GG known standard. 
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Cell extract protein concentrations were determined by the 
Pierce bicinchoninic acid (BCA) protein assay (Smith, 1985). The 
BCA assay is based on comparing unknown protein 
concentrations to known protein concentrations of bovine serum 
albumin (BSA) standards. BSA standards prepared were 10, 20, 
30, 40, 50, 60, 80, and 100 J..lg/1000 Jll of 1010 SDS in water. A 
standard curve was created by measuring the absorbance of the 
known BSA standards at a wavelength of 562 nm. The same 
quantity of experimental cell protein extract was measured at 562 
nm, the absorbance was noted, and the respective J..lg of protein 
per ml was calculated. Protein assays were performed in 
microtiter plates, allowing for multiple samples to be read and 
hence greater accuracy. The microplate reader was an Anthos ht 
II labtech. To micro titer plate wells 1 °J..lI of evenly distributed 
protein pellet sample along with 200 J..lI of BCA protein reagent 
was added. 
aSH RESYNTHESIS ASSAY 
Cell density was determined the day of the experiment using a 
Reichert bright line hemocytometer. Tissue culture flasks were 
removed from the incubator and gently shaken to evenly 
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distribute the cells. A quantity of cell suspension was prepared 
(12 mls) that would be adequate for the GSH reysnthesis assay: 2 
one ml samples for the negative time, for time 0 resuspension, 
and for resuspension times 20, 50, and 90 minutes post 
resuspension. 
Protocol; GSH resynthesis preparation: A one ml sample of cell 
suspension was removed from the flask and transferred to a 1.5 
ml microfuge tube. Duplicate samples were removed at zero time 
and for each other time point. The microfuge tubes, labeled with 
their appropriate times (t =-35 and -40), were centrifuged at 
13,000 x g in a Fisons micro centaur centrifuge for 20 to 30 
seconds. The supernatant was removed and discarded, then 500 
J.LI of lOOk peA and 15 I.d of 1 Ilmol/J.LI 'Y-GG was added to the cell 
pellet. 
To the cell suspension remaining in the flask DEM was 
added to give a final concentration of 200 mM DEM. The flasks 
were then returned to the incubator. 
The time necessary to deplete GSH to half base GSH 
concentration was determined from the GSH depletion assays. 
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For all AD cell lines, GSH depletion time was 35 minutes, and for 
control cell lines GSH depletion time was 40 minutes. 
At the pre-determined GSH depletion time, duplicate one­
ml aliquots were prepared, as previously described for GSH 
resynthesis preparation. The residual cell suspension remaining 
in the 25 cm2 flask was removed from the flask and transferred to 
a polypropylene centrifuge tube. The suspension was centrifuged 
at 1000 x g for three minutes in a Beckman model TJ-6 
centrifuge. The samples were removed from the centrifuge and the 
supernatant liquid was discarded. The cells were then returned 
to the 25 cm2 tissue culture flasks and incubated at 37°C, in an 
equal amount of RPM!. This was designated as resuspension time 
zero. 
At time points of 20, 50, and 90 minutes post cell 
resuspension, duplicate samples were removed and treated as 
previously described, (in "GSH resynthesis protocol") to determine 
GSH concentration by HPLC. 
Once the GSH resynthesis assay was complete, the 
precipitants were saved and assayed for protein concentration as 
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previously described. The cell extracts were prepared for HPLC as 
previously described. 
DTNB CNase ASSAY 
The DTNB (5-5'-dithio bis-2-nitrobenzoic acid) assay 
measures the quantity of product catalyzed by the enzyme CNase. 
This is done via colorimetric determination of the quantity of thiyl 
containing cysteine produced from the added substrate, 
cystathionine (Flavin, 1962 and Hargrove, 1987). The thiyl groups 
produced, bind to DTNB and yields para-nitrothiolate, a structure 
that highly resonates. Para-nitrothiolate is yellow and readily 
absorbs at 412 nm. Absorbance was measured, using a LKB 
Biochrom Ultrospec II spectrophotometer, and results were 
calculated using Beer's Law, an extinction coefficient of 13,600 m­
1cm-1, and an absorbency of 412 nm. CNase units were then 
calculated in mmoles of thiyl containing cysteine produced per 
minute per mg of protein. 
Prior experiments were conducted, using a variety of cell 
concentrations, in order to determine what CNase cell 
concentration would be within the linear slope of the protein 
standard curve (5 x 106 cells/ml). 
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Background thiyl group concentrations (background 
control) within the cell were determined by the addition of 200 III 
of 10% SDS to the time zero cell sample. Addition of SDS 
effectively inhibited all metabolic activity. All other reagents 
utilized in the CNase assay were then added to the control 
samples (DTNB, L-cystathionine, PLP, and EDTA). The reagent 
DTNB covalently bonded with all background thiol groups, 
producing para-nitrothiolate, thus giving the background thiyl 
concentration. 
To assay the enzyme CNase, the enzymes substrate, L­
cytstathionine, was added. L-cystathionine, added to a final 
concentration of 2 mM, was added to AD and control cell lines 
suspended in 0.1 M Potassium phosphate buffer (pH 7.35 KCL 
added) at time zero along with PLP and EDTA (Flavin, 1962 and 
Hargrove, 1987). PLP was added to a final concentration of 0.1 
mM and was utilized because it is a cofactor for the CNase 
enzyme. EDTA was added to a fmal concentration of 0.5 mM and 
was used as a chelator of unnecessary divalent metals. At 5 and 
10 minutes, 200 ~Ll of 100/0 SDS was added to the cells, thus 
stopping all metabolic reactions. Ten minutes after the addition 
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of SDS, 50 ,.d of 20 mM DTNB (DTNB diluted in 950/0 ethanol) was 
added, 
Subtracting the control thiol concentrations (time zero 
experiments) from the experimental thiol concentrations (enzyme 
allowed to catalyze substrate into product for 5 and 10 minutes) 
gave the total amount of cysteine produced from the enzyme 
CNase. For CNase specific activity, the moles of cysteine per ml, 
was divided by J.lg of protein per ml and then divided by time (5 
and 10 minutes). 
The statistical significance of the results obtained from the 
GSH (depletion and resynthesis) and CNase assays were 
determined by the student's t test. (Arkin, 1970). 
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RESULTS 
The working hypothesis was that AD lymphoblasts should 
have a higher level of GSH, an increased GSH resynthesis 
capability after GSH depletion, and an increased activity level of 
the enzyme CNase. All of these parameters would be indicative of 
an increased oxidative defense capability, as is suggested by AD 
pathophysiology. 
,The cell lines selected for the study were received from the 
OHSU Oregon Brain Aging Study program. There were three 
control lymphoblast cell lines (C-1066, C-152, & C-152) and three 
Alzheimer's diseased lymphoblast cell lines (AD-1085, AD-1137, & 
AD-864) investigated throughout the experimental process (as 
shown in Table 1). 
The GSH concentration in control cell lines was analyzed 
and the average concentration was calculated to be 0.1547 nmols 
GSH/mg of protein. The AD cell lines' base GSH concentration 
averaged 0.1342 nmoles GSH/mg of protein (Table 2). The 
standard deviations for AD and control cell GSH concentrations 
were 4.06 x 10-2 and 1.34 x 10-2 , respectively. Figure 1 shows a 
graphical comparison between the AD and control cells GSH 
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concentrations. Analysis of the mean AD and control GSH 
concentration data through statistical analysis, a t value of 
0.4097 was calculated (n=18): thus the differences in 
concentrations calculated were determined not to be significant, 
(p>0.3). 
Figures 2 through 4 display the rate of GSH resynthesis for 
the AD and control lymphoblast cell lines. The rates of GSH 
depletion for both AD and control cell lines are ostensibly parallel, 
as shown in Figure 2. The GSH resynthesis data was evaluated 
twenty minutes after washing off of DEM and resuspension in 
fresh RPMI (Figure 3). The AD cell lines GSH resynthesis mean 
slope was 4.225 x 10-4 (nmols GSH/mg of protein/min) and for 
the control cell lines the mean slope was 2.583 x 10-4 (Figure 3). 
The GSH resynthesis standard deviation for both the AD and 
control cell line slope was 1.99 x 10-7 and 0.711 x 10-7 , 
respectively. A t value was calculated to be 3.29, and therefore 
synthesis in AD lines was significantly faster, at P< 0.001. Figure 
4 depicts the GSH resynthesis concentration results relative to 
the initial GSH concentration. The percentage of GSH relative to 
initial was averaged for both the AD and control cell lines, and the 
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slope calculated. The AD mean slope was 0.2643 and the control 
slope was 0.1703. The standard deviations were 0.1089 for AD 
and 0.024 for the control. Synthesis rates were significantly 
different at p<O.OOl. 
Figure 5 displays the significant differences of individual 
cell lines GSH resynthesis rates. The control cell line Co203 GSH 
resynthesis rate was significantly different from that of AD1085 
(P<O.OOl) and AD864 (P<0.005). The Co152 resynthesis data 
statistically differed from AD 1085 (P<O.OOl) and AD864 (P<0.005). 
Co166 resynthesis data significantly differed from only AD 1085 
(P<O.OOl). The AD1085 resynthesis data significantly differed 
from all five other cell lines (P< 0.001 for all control and ADl137) 
(P<0.005 for AD864). The ADl137 resynthesis results 
significantly differed from AD864 (P<0.005) and AD1085 
(P<O.OOl). AD864 resynthesis results differed from four other cell 
lines ( P<0.005 compared to control 203, 152, 166, and AD 1085 
and 1137), but did not statistically differ from control 166. 
Cystathionase assays for the AD and control cell lines are 
displayed in Figure 6 and are in units of moles of thiol containing 
cysteine produced/min/mg of cellular protein. The AD cell line 
35 

mean CNase production was calculated to be 2.2079 x 10-10 
(n=18) while 1.426 x 10-10(n=18) was obtained for the control cell 
lines. The standard deviation was 4.4866 x 10-11 and 1.53 x lO­
II for the AD and control cell lines, respectively. A twas 
calculated to be 7.824, indicating that CNase specific activity in 
AD cell lines was statistically larger than control cell lines 
(p<O.OOl). 
Figures 7 through 12 represent AD and control cell lines 
individual GSH depletion and resynthesis concentrations at time 
points of -35 (AD, Fig 10-12), -40 (Control, Fig 7-9), and at times 
0, 20, 50, and 90 minutes (for all 6 cell lines). The graphs also 
displays the individual standard deviations (SD) for all time 
points' GSH concentrations. 
Figure 13 displays four different HPLC graphs from the AD 
cell line 1085. Retention time (RT) of 38.10 minutes represents 
the internal, standard g-GG cellular concentrations, and RT of 
42.01 minutes represents GSH cellular concentrations. In Figure 
13, four individual HPLC graphs are displayed (-35b, Oa, SOb, and 
90a), all at different time points throughout the resynthesis assay. 
In Figure 13, Graph -35B represents GSH concentration before 
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the addition of DEM. Graph OA represents the GSH concentration 
at the time of cellular resuspension in DEM-free medium. Graph 
SOB and 90A represents the GSH concentrations at 50 and 90 
minutes post-resuspension. 
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DISCUSSION 
The oxidative stress hypothesis has suggested that reactive 
oxygen species may be of significance in the development of AD. 
The ultimate question to be investigated is whether AD patients 
have an increased sensitivity to oxygen free radicals or an 
increased level of free radical formation. An increased sensitivity 
to oxygen free radicals would be indicative of a decreased level of 
free radical defense mechanisms, such as GSH. The alternative, 
an increased level of free radical formation could be caused by 
nuclear and mitochondrial mutations (Davis, 1997) or by external 
factors. Intracellular generation of ROM's, such as H202 and 02-' 
results in increased transcription of the regulatory and catalytic 
subunits of the GSH synthesizing enzyme g-glutamylcysteine 
synthetase (Moellering, 1998). Also noted, ROM's increase the 
activity of the transulfuration pathway and the cysteine supplying 
enzyme, CNase (Reed, 1995). If the etiological foundation of AD 
pathology is based on an increased amount of free radical 
formation, then an increased level of free radical defense 
mechanism would be expected throughout all afflicted AD cells. 
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In these studies, OEM was the GSH depleting agent used 
throughout the depletion and resynthesis experiments. OEM 
conjugates to GSH through the enzymatic catalysis of GST's. 
GSH nucleophilically attacks OEM's carbon-carbon double bond, 
beta to a keto group, the result is a stable molecule, which has 
effectively removed GSH. 
The results of these experiments showed no statistical 
difference between AO and control cell lines for resting GSH 
cellular concentration (Figure 1 and Table 2). This result is in 
opposition to one of the three parameters investigated throughout 
this study. These results may be a phenomenon based on GSH's 
high degree of turn over, or on the feed back inhibition of GSH 
synthesis. GSH is reported to have a half life of 192 minutes in 
the rat liver (Meredith, 1986), 240 minute half life in the kidney 
(Scott, 1993), 114 minutes in resting macrophges (Rouzer, 1982), 
and 59.5 hours in the brain. (Chang, 1997). With such a quick 
and varied GSH turnover rate throughout systemic tissues, GSH 
level could be maintained at an appropriate level for defense 
against insult. Maintenance of adequate GSH concentrations can 
be sustained be recycling GSH and GSSG from an oxidized to a 
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reduced form, and by GSH resynthesis from the amino acid 
components glycine, glutamate, and cysteine. The quick turnover 
rate seem to be an appropriate rational in support of the findings 
that GSH levels were not highly elevated in AD afflicted 
lymphocytes versus the control lymphocytes tested in vitro. The 
second notable process was that feedback inhibition of GSH 
synthesis helps to give a rational interpretation for the unelevated 
GSH concentrations. 
Balazs and Leon determined the levels of GSH in 12 regions 
of the brain from AD patients and age matched control patients 
(Balazs, 1994). The cells were removed from the AD and control 
subjects' brains within 7.3 hours postmortem for AD and 5.8 
hours postmortem for controL These investigators reported no 
significant difference in GSH levels in AD brain as compared to 
control tissue samples. They also reported no overall difference in 
GSH concentrations between the 12 different brain regions. The 
investigators used the GSH disulfide reductase DTNB recycling 
assay and measured DTNB products using the same procedures 
used in the current work. 
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The second parameter investigated in this study was the 
GSH resynthesis capability in AD cell lines as compared to the 
control cell lines. Figures 2, 3, 4 and 5 display the combined 
results of GSH resynthesis experhnents. Figures 7 through 12 
display individual cell lines GSH concentrations at different time 
points, and also displays relative standard deviations. Figure 2 
shows that while the rates of depletion of GSH between AD and 
control lymphoblats were indistinguishably parallel, the 
resynthesis rates differed. The amount of GSH depletion is also 
displayed in Figure 2. Although the goal was to obtain a 50% 
depletion concentration (as compared to initial GSH 
concentration), there were some variations throughout cell lines. 
Sierra-Rivera, et al. noted that the resynthesis rates of GSH were 
indistinguishable between GSH depletion concentrations of 20­
70% (Sierra-Rivera, 1994). Figure 3 represents the GSH 
resynthesis data from 20 to 90 minutes after DEM washing and 
cellular resuspension in DEM-free medium. Resynthesis data 
was analyzed 20 minutes after resuspension, thus allowing all cell 
lines to have comparable resynthesis parameters. The mean 
slopes for all three AD and control slopes were averaged and 
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compared with their standard deviations. A significant difference 
was calculated differentiating the two mean slopes, with a 
probability of greater than 99.9% (P<0.001). The AD 
lymphoblasts showed an increased resynthesis capability as 
compared to the control cell lines mean resynthesis rate. The AD 
mean resynthesis slope was 4.225 x 10-7 nmols GSH 
produced/mg protein/minute, as compared to the control cells 
2.583 x 10-7. 
Figure 4 displays the GSH resynthesis capabilities of AD 
and control cell lines relative to the initial GSH concentrations. 
The AD and control GSH resynthesis slopes were averaged, and 
the mean rates were compared. Again, AD lymphoblasts showed 
an elevated capacity to resynthesis GSH as compared to control 
cell lines. 
Figure 5 displays the significant difference of individual 
resynthesis slopes, as obtained from figure three data. AD cell 
lines Ad1085 and 864 were distinguishable from all other cell 
lines, except AD 864 and control 166 were shown to be of no 
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significant difference. Adl137 resynthesis data was similar to all 
other control cell lines, but the mean resynthesis of all three AD 
cell lines did statistically differ from the mean of all the control 
cell lines tested (Figures 3 and 4). 
GSH is synthesized intracellularly from three free amino 
acids in two steps. First, the gamma carboxyl group of glutamate 
is activated by ATP and forms an amide with the amino group of 
cysteine with the help of the enzyme gamma-glutamyl cysteine 
synthetase. The second step involves a similar activation of the 
cysteine carboxyl group, by ATP, allowing the dipeptide to 
condense with the free amino acid glycine. The second enzyme, 
gamma glutamylcysteine synthetase, which catalyzes the 
condensation of the dipeptide and glycine, is feedback inhibited 
by GSH. This feedback inhibition could aid in the rationalization 
of the findings that GSH concentration in AD versus control cells 
did not statistically differ. Notably, mean GSH resynthesis 
capability was elevated in AD versus control lymphoblast cell 
lines. 
The limiting reagent in de novo aSH synthesis and 
resynthesis is the amino acid cysteine. CNase is capable of 
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providing cysteine through the utilization of methionine's sulfur 
atom and serine's carbon skeleton. The transulfuration pathway, 
as described in the introduction, provides cysteine when GSH 
biosynthesis is at elevated levels and when the cysteine 
concentrations are below glutathione's synthesis demands for the 
amino acid. Therefore, cystathionine's capabilities to provide 
cysteine in times of high GSH demand are essential too cellular 
oxidative defense mechanisms. When cystathionine is cleaved by 
CNase alpha-ketobutyrate, ammonia and the thiolate ion of 
cysteine (cys-) are immediately produced. Immediately after lysis, 
cys- can perform disulfide exchange with DTNB. The disulfide 
exchange with DTNB produces the highly resonating para­
nitrothioloate anion. This anion is easily detectable at a 
wavelength of 412 nm, and can be measured with a 
spectrophotometer. The CNase experimental assays executed 
denoted an increased capability of AD lymphoblast cell lines as 
compared to control cell lines to produce cysteine from 
cystathionine (Figure 6). The AD lymphoblast cell lines showed 
1.45 times the level of CNase specific activity of control 
44 

lymphoblast cell lines. This data was confirmed with a greater 
than 99.9% significant difference (P<O.OOl). 
In addition, it is important to note that the control 166 cell 
line showed an increased GSH resynthesis capability and an 
increased CNase level as compared to the other two control cell 
lines (Figures 3, 4 and 5). The explanation for this atypical cell 
line can be explained by the possibility that the subject tested is 
metabolically in a state of increased oxidative damage. This 
subject may possibly have a potential for AD pathogenesis, 
although the donor is still disease free. 
Marcus, et al. analyzed neurological tissue samples from 
the brain of post-mortem confirmed AD afflicted individuals and 
compared those results to tissue samples from age matched 
control patients (Marcus, 1998). The investigators analyzed the 
activity of oxidative defense enzymes throughout tissue samples 
from frontal, temporal, and cerebellar brain regions. 
The investigators reported an increase in overall lipid 
peroxidation throughout all three tissues, determined by the 
production of thiobarbituric acid-reactive products (TBARS). In 
AD tissue samples, the enzyme superoxide dismutase (SOD) was 
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reported to be statistically higher in the frontal and temporal 
brain regions as compared to control cell tissue. A significant 
decrease in catalase enzymatic activity was reported in the 
temporal brain region. In contrast, the investigators reported no 
significant difference in the activity of the enzyme GPX. They 
reported a 120/0 increase (AD vs. control) in GPX activity in the 
frontal region, almost equal enzyme activity in the temporal 
region, and a 28% decrease in GPX activity in the cerebellum 
(although none of the data was statistically significant). As stated 
above, CAT is limited to the peroxisomal compartments within 
cells and SOD only converts the superoxide anion radicals into 
hydrogen peroxide, leaving the brunt of hydrogen peroxide to be 
neutralized by GPX. The fact that they reported relatively no 
difference in the GPX activity further supports the theory that the 
AD etiology stems from an increase in oxidative damage and not 
from a decrease in oxidative defense mechanisms, which is 
contradictory to their reported theory. 
Lovell, et al. determined the levels of the GSH enzymes GPX 
and of GSSG-R (Lovell, 1995). GSSG-R reduces the oxidized form 
of GSH, GSSG, allowing the two to cycle between the reduced 
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thiol form (GSH) and an oxidized form (GSSG) (in which two GSH 
tripeptides are linked together by a disulfide bond with the help of 
NADPH). The investigators reported a statistical increase in GPX 
and GSSG-R activity throughout two regions of AD brain as 
compared to control brain tissue samples. This evidence is not 
congruent with the previous study, but does support the theory of 
increased oxidative defense mechanisms throughout AD tissue. 
. E-4-Hydroxy-2-nonenal (HNE) is an electrophilic species 
that can covalently modify cellular macromolecules, and is 
produced as a by-product of lipid peroxidation. Oxidative stress 
causes lipid peroxidation, an autocatalytic process that damages 
lipid containing structures and yields HNE along with 
malondialdehyde (MDA). The electrophilic species HNE cross-links 
proteins by interacting with cellular nucleophiles, particularly 
lysine, histidine, serine, and cysteine residues. The investigators 
Montine, et al. investigated HNE's cytotoxicity by adding HNE, an 
HNE analog, and MDA to cultured neuroglia (Montine, 1996). 
They were investigating the mechanism to which HNE causes cell 
death. Their data showed that HNE can cross link cytoskeletal 
proteins and is directly cytotoxic to cell cultures. However, the 
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HNE analog and MDA did not cross link proteins and was not 
shown to cause cell death. These investigators theorized that 
HNE might be responsible for the disulfide bond-independent 
cross linking of the proteins in NFT'S. These experimental results 
further support the theory that increased oxidative damage is the 
causative agent of AD. Since HNE is a direct product of lipid 
oxidative damage (peroxidation), a mechanism for the production 
of cross-linked cytoskeletal protein from peroxidation damage can 
be inferred. 
Smith, et al. studied overall protein oxidation in AD versus 
age matched control brain samples (Smith, 1991). Tissue samples 
were taken from the brain fronta1lobe and occipital lobe of each 
subject. The protein oxidation state was determined by 
measuring brain carbonyl content. Excessive oxidative 
modification of proteins in AD patients suggests an increase in 
overall oxidative damage, as is suggested in the oxidative stress 
hypothesis. The investigators provided statistically significant 
evidence that AD brain samples had an increased amount of 
protein oxidation as compared to control tissue samples. 
Glutamine synthetase is the enzyme that catalyzes the conversion 
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of glutamate to glutamine. Mixed function oxidation is a site­
specific oxidative modification of proteins, occurring near the 
metal containing catalytic sites of particular enzymes, as is the 
case with glutamine synthetase. These investigators continued to 
report a statistical decrease of glutamine synthetase activity in AD 
brain samples as compared to control tissue samples. 
B-Hydroxy-2'-deoxyguanosine (OHBdO) is a biomarker of 
oxidative DNA damage. The investigators Morocci, et al. used 
OHBdO to differentiate between the DNA oxidation state of 
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) in AD brain 
tissue samples as compared to control samples (Morocci, 1994). 
They reported a statistical increase in oxidative damage to the 
nDNA of AD brain samples as compared to control tissue 
samples, with an increase throughout all brain regions studied. 
Furthermore, they reported an even higher level of mtDNA 
damage in AD as compared to the control brain tissue samples. 
The mtDNA damage due to oxidation was drastically higher in AD 
versus control samples as compared to the nDNA oxidative 
damage. The higher mtDNA versus nDNA' damage supports the 
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theory that an ETC mutation, specifically a COX mutation, has 
resulted in elevated levels of oxidative stress in AD pathology. 
There is an abundance of data supporting the oxidative 
stress hypothesis. The oxidative stress hypothesis is so appealing 
as an etiological base for AD because of the fact that an 
accumulation of oxidative damage over time could account for the 
late life onset and slow progressive nature of the neurological 
disorder. Increased amounts of Fe++, AI++, and Hg++ have been 
reported in AD brain tissue (Markesbery, 1993), and this is 
indicative of increased oxidative damage. Many parameters 
support the increase in oxidative damage theory: increased lipid 
peroxidation, increased HNE levels, increased protein and DNA 
oxidation, the presence of NFT's, SP's and ~-AP. 
As stated in the discussion, ~-AP elevates oxidative damage 
in cells (Behl, 1992), and is capable of generating free radicals by 
stimulating microglia to produce neurotoxins such as ROS, RNS, 
TNF-a, Apo E. The microglial activation also stimulates the 
complement cascade proteins activation, further leading to cell 
death. Because genetic mutations associated with familial AD 
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result in an ultimate increase in insoluble ~-AP, and because of 
the genetic mutations associated with sporadic AD (COX 
mutation), an overall increase in oxidative insults are resultantly 
associated with AD genetic mutations. 
The data reported in this study extends evidence which 
support the oxidative stress hypothesis. Briefly, In this study, AD 
cell lines exhibited ubiquitously higher levels of GSH resynthesis 
capabilities and an increase in CNase levels as compared to age 
matched control cell lines. Data accumulated from this study, 
taken in context with other experimental data, discussed 
throughout this paper, provides considerable evidence that 
increased oxidative insult, not decreased defense mechanisms, 
are probably at the heart of the Alzheimer's disease pathogenesis. 
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CELL TYPE (GSH) nmoVmg 
cell protein Standard deviation 
Co203 (n=7) 0.116997 0.04617 
Co166 
(n=6) 
0.19778 0.037486 
Co152 
(n=6) 
0.1496 I 0.033223 
Ave Co (n=19) 0.1547 0.0134 
Adl085 (n=10) 0.17355 0.023612 
Ad 864 
(n=6) 
0.14733 0.03538 
Ad1137 
(n=6) 
0.1556 0.04254 
Ave Ad 
(n=22) 
0.1342 0.0406 
I 
TABLE 2: Alzheimer (Ad) and Control (Co) resting cellular GSH 
concentration, labeled with ralative Standard deviations. Cellular 
GSH concentration was measured by a method of HPLC and all GSH 
concentrations were normalized to cellular protein 
concentrations, as described In "materials and methods'" Results 
show no statistical difference between Ad and Co cell lines. 
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Figure 1. Glutathione levels compared between Ad and Co 
lymphoblast cell lines. Alzheimer (Ad) vs. Control (Co). 
Cellular GSH levels were determined by a method of HPLC as 
described in "materials and methods". Error bars show mean 
SD. Results showed no statistically significant difference 
between Ad and Co GSH concentrations. n displays the number of 
replications. 
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Figure 2. Mean GSH depletion and resynthesis concentrations for Ad 
and Co cell lines. Alzheimer (Ad) and Control (Co) lymphoblast 
cell lines were treated with 200mM OEM, the GSH depletion agent, 
then resuspended at time 0 in OEM-free medium (as described In 
"materials and methods"). Ad and Co cells show parrallel 
glutathione depletion rates. Resynthesis rates differ and Individual 
SO are displayed in Figures 7-12. Concentration of GSH was 
normalized to cellular protein and GSH was measured by a method 
of HPLC. 
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measured by a method of HPLC and GSH concentrations were 
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Fieure 5: Significant difference between Alzheimer's 
diseased (Ad) and control (Co) lymphoblast cell lines 
GSH resynthesis rates. Figure displays relavency of 
individual cell line resynthesis rates, compared with 
all other cell lines. 
(ns) = no significant difference 
(*) = Statistically significant difference (P<O.05) 
(**)= Statistically significant difference (P<O.001) 
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Figure 6. Comparison of cystathionase (CNase) activity In 
Alzheimer's diseased (Ad) and Control (Co) lymphoblast cell lines. 
After the addition of the CNase subsrate, cystathionine, the enzyme 
activity was measured by colorimetrically determining the amount 
of product (thiol containing cysteine)produced in a quantity of 
mols/minute/mg of protein. Procedures of CNase assay are 
discussed In "materials and methods". Resluts show a statisicially 
significant difference between the mean AD and Co CNase activity 
(P<0.001). 
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Figure 7. GSH depletion and resynthesis graph for the 
control (Co) 203 lymphoblast cell line. Y error bars 
represent mean SO for Co 203 GSH concentrations. Cell 
lines were treated with 200mM OEM and were then allowed 
to replenish GSH in OEM-free medium. GSH levels were 
determined by a method of HPLC, as described in "materlals 
and methods". GSH content was normalized to cellular 
protei n concentrations. 
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Figure 9. GSH depletion and resynthesis graph for the control 
(Co) 152 lymphoblast cell line. V error bars represent 
mean SO for Co 152 GSH concentrations. Cell lines were 
treated with 200mM OEM and were then allowed to replenish 
GSH in OEM-free medium. GSH levels were determined by a 
method of HPLC, as described in "materials and methods". 
GSH content was normalized to cellular protein 
concentrations. 
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Figure 10. GSH depletion and resynthesis graph for the 
Alzheimer's disease (AD) 1085 lymphoblast cell line. V 
error bars represent mean SO for AD 1085 GSH 
concentrations. Cell lines were treated with 200mM OEM 
and were then allowed to replenish GSH in OEM-free medium. 
GSH levels were determined by a method of HPLC, as 
described in "materials and methods". GSH content was 
normalized to cellular protein concentrations. 
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Figure 11. GSH depletion and resynthesis graph for the 
Alzheimer's disease (AD) 864 lymphoblast cell line. Y error 
bars represent mean SO for AO 864 GSH concentrations. Cell 
lines were treated with 200mM OEM and Were then allowed to 
replenish GSH In OEM-free medium. GSH levels were 
determined by a method of HPLC, as described in "materials and 
methods". GSH content was normalized to cellular protein 
concentrations. 
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Figure 12. GSH depletion and resynthesis graph for the 
Alzheimer's disease (AD) 1137 lymphoblast cell line. Y error 
bars represent mean SO for AD 1137 GSH concentrations. Cell 
lines were treated with 200mM OEM and were then allowed to 
replenish GSH in OEM-free medium. GSH levels were 
determined by a method of HPLC, as described in "materials 
and methods". GSH content was normalized to cellular protein 
concentrations. 
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Figure 1 3: Alzheimer's disease (AD) cell line 1 085, high 
performance liquid chromatography (HPLC). The graphs show an 
example of AD 1085 HPLC data results. Retention time (RT) of 
38.10 minutes represents the Internal standard gamma-glutamyl 
glutamate (g-GG) within the cellular suspension sample. The RT of 
42.01 minutes represents the quantity of glutathione (GSH) within 
the cellular suspension sample. The quantities were normalized to 
cell protein (J.1g of cell protein! ml). Noted on each Individual graph 
Is the time of the sample, a-35 represents the sample before the 
addition of OEM. Time 0 represents the sample at the time of 
cellular resuspenslon In OEM-free medium, and times of 50 and 90 
minutes represents the times post cellular resuspension in OEM-free 
medium. ';. 
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